Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002041 · ClinicalTrials.gov registry record · NA

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

A NA study of HIV Infections and Candidiasis, Esophageal, sponsored by Bristol-Myers Squibb.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002041: Completed NA study of HIV Infections and Candidiasis, Esophageal, sponsored by Bristol-Myers Squibb.

NCT00002041 is a NA study of HIV Infections and Candidiasis, Esophageal that has completed, run by Bristol-Myers Squibb. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002041, a NA study of HIV Infections and Candidiasis, Esophageal, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis. To determine if low-dose amphotericin B is less toxic than standard dose therapy during a limited treatment period. To evaluate pharmacokinetic and pharmacodynamic parameters of the two different dosing regimens.

Conditions Studied

HIV Infections Candidiasis, Esophageal

Interventions

  • DRUG Amphotericin B

Study Locations (1)

New Jersey

  • Bristol - Myers Squibb Co - Princeton

Trial Details

FieldValue
Phase NA
Bristol-Myers Squibb

1,025 total trials

What the finished NCT00002041 record still lists

NCT00002041 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Amphotericin B is the first listed.

NCT00002041 reports a single indexed study location in New Jersey.

Frequently Asked Questions

What is clinical trial NCT00002041 about?

NCT00002041 is a clinical study titled "Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients". To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis. To determine if low-dose amphotericin B is less toxic than standard dose therapy during a...

What is the current status of trial NCT00002041?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002041 study?

This clinical trial studies the following conditions: HIV Infections, Candidiasis, Esophageal.

What interventions are being tested in trial NCT00002041?

The interventions under investigation include: Amphotericin B (DRUG).

Who is sponsoring clinical trial NCT00002041?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002041 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002041, the US trial registry maintained by the National Library of Medicine. NCT00002041 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.